Post-transplant care after allogeneic hematopoietic stem cell transplantation
Journal Title: OncoReview - Year 2015, Vol 5, Issue 1
Abstract
Around 25,000 people annually worldwide are subject to the procedure of allogeneic hematopoietic stem cell transplantation (HSCT). As the number of procedures has been on the rise, post-transplant care is becoming an essential part of work at transplant centres and general practitioners’ offices. Advances in technology and supportive therapies extend long-term survival of patients after HSCT, which increases the risk of complications resulting from exposure before, during and after transplant procedures. The complications may lead to significant morbidity, deteriorated quality of life, and late mortality in patients who have received hematopoietic stem cells. Statistical analyses have shown that the survival rate of post-HSCT patients is ca. 30% lower than expected, and that infections, organ failure and secondary cancers lead to mortality in this population of patients.
Authors and Affiliations
Ewa Karakulska-Prystupiuk, Jadwiga Dwilewicz-Trojaczek
Keywords
Related Articles
- EP ID EP67777
- DOI -
- Views 191
- Downloads 0
Krwioplucie – rak czy zatorowość płucna?
Pacjenci onkologiczni to grupa o zwiększonym ryzyku wystąpienia zatorowości płucnej. Zarówno w obrazie klinicznym zatorowości płucnej, jak i w przebiegu choroby rozrostowej może wystąpić krwioplucie. Jest ono zawsze obja...
Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report
Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...
Side effects control in the chemotherapy with everolimus: single-center experience
BACKGROUND: Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of p...
Terapie celowane w nowotworach neuroendokrynnych
Leczeniem z wyboru nowotworów neuroendokrynnych układu pokarmowego jest leczenie operacyjne, a jego zakres zależy od stopnia zaawansowania nowotworu. W przypadku choroby zaawansowanej stosowane są metody leczenia zachowa...